Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Selection, Unmet Needs, and Efficacy Data
This video was recorded prior to the FDA approval on September 17, 2024, of ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage II and III early breast cancer at high risk of recurrence.
Comments 0
Login to view comments.
Click here to Login
